The dopamine receptor agonist apomorphine has been used successfully to treat on-off swings in Parkinson's disease. Its value as a predictor of dopa responsiveness in idiopathic Parkinson's disease (IPD) was assessed and its potential role in differentiating IPD from the Parkinsonian plus syndromes (PPS) of multisystem atrophy, progressive supranuclear palsy and olivopontocerebellar atrophy was investigated. The response to an injection of apomorphine was observed in 20 patients with IPD and eight with PPS after being off levodopa for 12 hours. Patients were reassessed after taking levodopa for one month. Nineteen of the 20 patients (95%) with IPD showed a positive response to apomorphine and 18 (90%) to oral levodopa. 
D F D'Costa, R J Abbott, I F Pye, P A H Millac Abstract The dopamine receptor agonist apomorphine has been used successfully to treat on-off swings in Parkinson's disease. Its value as a predictor of dopa responsiveness in idiopathic Parkinson's disease (IPD) was assessed and its potential role in differentiating IPD from the Parkinsonian plus syndromes (PPS) of multisystem atrophy, progressive supranuclear palsy and olivopontocerebellar atrophy was investigated. The response to an injection of apomorphine was observed in 20 patients with IPD and eight with PPS after being off levodopa for 12 hours. Patients were reassessed after taking levodopa for one month. Nineteen of the 20 patients (95%) with IPD showed a positive response to apomorphine and 18 (90%) to oral levodopa. In the PPS group, two patients (25%) responded to the apomorphine injection but not to oral levodopa. Apomorphine produced severe drowsiness in the PPS patients. It is suggested that the test can predict dopa responsiveness in IPD and may be of help in confirming a doubtful diagnosis. It has potential value in differentiating IPD from PPS.
Apomorphine, a powerful dopamine receptor agonist, is a useful treatment for the on-off fluctuations in Parkinson's disease. '2 Recent reports"' suggest that it might be used to predict levodopa responsiveness in Parkinsonian syndromes. Our study was set up to investigate this possible application further and to see whether idiopathic Lewy body Parkinson's disease (IPD) could be distinguished from the Parkinsonian plus syndromes (PPS) of multisystem atrophy (MSA), progressive supranuclear palsy (PSP) and olivopontocerebellar atrophy (OPCA). In addition we wanted to assess whether an uncertain diagnosis of IPD could be confirmed. 27-6% (range 15-75%) to 40-0 (3-0) after apomorphine and to 38 3 (3-0) on levodopa. The walking times ( fig 2) were 31-8 (6 6) seconds (baseline), 21-0 (4-0) seconds after apomorphine, and 22-1 (5-1) seconds on levodopa. The improvement in the mean tap score and walking times after apomorphine and levodopa was highly significant (p < 0-01).
The mean (SEM) scores for age and sex matched controls with no neurological disability were 57-7 (1 -7) for tapping and 13-5 (0-5) for walking. Thus even after treatment, the scores were below that of controls. The mean apomorphine dose required to elicit an optimal response was 3-7 mg. Three patients required 8 mg and one required 10 mg to show a response. This response was noted within 15 minutes of the injection in all but three of the responders in whom the onset took place at 30 minutes. The duration of response was 75 minutes (range 45-120). Eighteen of the 19 responders to apomorphine showed a similar positive response to levodopa. There was a highly significant (p < 0-001) positive correlation between the changes in tapping after apomorphine and levodopa (r = 0-88), and between the changes in walking after apomorphine and levodopa (r = 0 96). There was a negative correlation between tapping scores and walking times after apomorphine (r = -064) (p < 0-005) and after levodopa (r = -0-49) (p < 0-05) reflecting that as tapping scores improved, walking times were reduced. Two responders to the tap test showed no change in walking. One patient showed a positive response only in walking and not tapping-as the lower limbs were mainly involved. Only one patient (5%) failed to respond to either apomorphine or levodopa. A few patients noted a significant improvement in rest tremor after apomorphine. In the PPS group, two out of eight (25%) responded to apomorphine but neither of these responded to oral levodopa. The mean duration of benefit (75 minutes) was similar to the IPD group. The responses to apomorphine were quite dramatic-one patient with MSA for four years showed a 50% improvement in tapping and 30% improvement in walking. The other patient with OPCA for two years showed a 20% improvement in both tapping and walking. Two other patients who obtained no benefit with apomorphine improved with levodopa. Of these, one with PSP for eight years showed a 40% improvement in both tapping and walking with levodopa and the other with MSA for three years a 30% improvement in walking. The remaining four patients (50%) were unable to tolerate oral levodopa preparations developing nausea, vomiting and malaise even with low doses. Baseline tapping, mean (SEM), 20 (2-8), and walking, 22-8 (4-7), scores did not change significantly after apomorphine 22-6 (4 6), 20 5 (4-5) or after levodopa, 20 (1 7), 18-1 (22).
Adverse reactions to apomorphine were mild in the IPD group and included nausea, vomiting, dizziness, flushing, sweating and pallor. This affected 10 of 20 patients. One patient developed transient priapism. In the PPS group the side effects were more pronounced and occurred in all patients and at lower dosage than for IPD. In addition the PPS group had quite marked drowsiness which was present in all patients. 
to apomorphine these patients then had the opportunity of increasing their current doses or receiving a different levodopa preparation.
The single non-responder to apomorphine and levodopa in the IPD group has shown no response to levodopa infusions and has been unable to tolerate oral levodopa. He was aged 50 and had typical features of IPD with a rest tremor, rigidity and a bradykinetic stooped gait. He had two negative CT scans three years apart. It will be interesting to see whether in the long term he develops PPS. The other dopa non-responding patient was aged 72. He had classic features of IPD four years ago and he initially responded to treatment, but has not done so recently. He had a 35% improvement in tapping after apomorphine but no change with levodopa. He is thus a late non-responder and would be suitable for apomorphine.
The mean tap score after apomorphine or levodopa remained 68% of that of age and sex matched controls. Likewise, the walking time was about 60% longer than that of controls. Despite apparently optimal treatment, a return to normal function was still not achieved.
In the PPS group, two (25%) showed a positive response to apomorphine but not to oral levodopa whilst two non-responders to apomorphine showed a positive response to levodopa. Thus the test may not be able to predict reliably dopa responsiveness in PPS patients or differentiate IPD from PPS in all cases. Drowsiness appears to be a feature unique to the PPS group even with low doses, and this in itselfmay help point to a diagnosis of PPS rather than IPD. Four (50%) felt a lot worse after the apomorphine with an objective deterioration in their performance. Three of these were unable to tolerate levodopa but one showed an improvement in walking with levodopa.
In the study by Hughes et al,3 apomorphine accurately predicted the response to long-term levodopa in 90% of the Parkinsonian patients.
We obtained a similar result in our IPD patients. There will thus still be 10% of patients with a negative response who will respond to prolonged levodopa-hence a negative response should not rule out a trial of levodopa.
In the PPS group, our findings differed from those of Hughes et al. They obtained two falsenegatives out of 35 patients and no falsepositives. We observed two false-negatives out of eight patients and two false-positives. Additionally, our PPS patients had a higher incidence of more pronounced side effects than the IPD group unlike the study by Hughes et al where the two groups had broadly similar side effects. Although we studied only eight patients with PPS, we believe the profound drowsiness after apomorphine helps point to a diagnosis of PPS.
Hughes et al compared the responses to apomorphine, an oral levodopa challenge and the response to continued levodopa therapy. They found a similar sensitivity between apomorphine and a single levodopa challenge. We did not use the single levodopa challenge. Our study compared responses to apomorphine and prolonged levodopa and we used a maximum of 10 mg of apomorphine as did others7 compared with 4 
